Tandem VHH/Nanobody (single domain antibody) – Introduction
Virus-like particles (VLP) Platforms for immunogens, vaccines and drug carriers
Antibody-drug Conjugate (ADC): Pre-made ADC benchmark, MOA, Production and QC
Neutralizing antibodies of virus (SARS2, HIV, HBV, Rabies, RSV, Ebola, Influenza)
Immunoglobulin Fc receptors for Fc&Fc Receptor binding assay
ILIBRA-HuEasy Monoclonal antibody (mab) humanization service (fully humanized ab)
Single domain antibody (Nanobody)
SOCAIL MEDIA
Since 1975, monoclonal antibodies have been successfully used for the diagnosis and therapeutics. In 1993, heavy-chain-only antibodies which bind to antigens was discovered in camelids. The variable domain of heavy chain antibody (VHH) was called as nanobodies and it was anticipated as the better therapeutic antibodies in future due to its high stability, refoldability, and manipulable characteristics. VHH has also been effectively used for the diagnosis, bioimaging, immunoassay and affinity purification.
View the Knowledge base of Tandem VHH/ Nanobody(single domain antibody):
– Tandem VHH/Nanobody (single domain antibody): Structure, Production, Application and Products
– Tandem VHH/Nanobody (single domain antibody) – Introduction
– Structure and Physicochemical Features of Nanobody (single domain antibody)
– Nanobody (single domain antibody) production
– Application of nanobodies (single domain antibodies)
– Advantages and limitation of Nanobodies (single domain antibodies)
– GeneMedi’s products list of Nanobodies (single domain antibodies)
